Public consultation - Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18
Overview
The National Health and Medical Research Council (NHMRC) is conducting public consultation on the Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18 (Advice on Puberty Suppressants) in accordance with Section 13 of the National Health and Medical Research Council Act 1992 (NHMRC Act).
Public consultation will be open for 9 weeks from 1pm AEDT Monday 16 November 2026 to 1pm AEDT Monday 18 January 2027. If you have any questions or need further information while the consultation is open, please email consultation.genderguidelines@nhmrc.gov.au.
What is the Advice on Puberty Suppressants about?
This Advice on Puberty Suppressants focuses on the use of puberty suppressants in the care of people aged under 18 with gender incongruence.
Work is continuing on the full national clinical guidelines for the care of trans and gender diverse people aged under 18, which will include advice on the use of hormones and psychosocial support. The full guidelines are expected to be released for public consultation by early 2028.
The Advice on Puberty Suppressants was developed with advice from the multidisciplinary Gender Guidelines Development Committee and is supported by a systematic review of the evidence, in line with NHMRC’s Standards for Guidelines and Guidelines for Guidelines, and the internationally recognised GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to guideline development.
Why is NHMRC conducting public consultation?
Public consultation is an integral part of NHMRC’s guideline development process.
In accordance with Section 13 of the National Health and Medical Research Council Act 1992 (NHMRC Act), draft NHMRC guidelines and advice undergo public consultation for a minimum of 30 days before they are finalised.
Individuals and organisations interested in the Advice on Puberty Suppressants are encouraged to participate in this process and provide feedback, which will be considered before the guidelines are finalised.
What is the scope of this consultation?
This consultation is specific to the Advice on Puberty Suppressants.
Submissions should address the content of the Advice on Puberty Suppressants, including the proposed recommendation and good practice statements, the interpretation of the evidence in the Advice on Puberty Suppressants, implementation considerations, and any other matters directly relevant to the Advice on Puberty Suppressants.
There are 13 background questions (Questions 2 – 14) and 4 questions related specifically to the Advice on Puberty Suppressants (Questions 15 – 18). You do not have to respond to all questions. There is a 500-word limit for questions relating specifically to the Advice on Puberty Suppressants. Any other comments about the Advice on Puberty Suppressants can be provided in Question 19 which has a 1000-word limit. There will not be an opportunity to upload documents as part of your submission.
Respondents are asked not to include any sensitive personal information, such as medical history about themselves or others. Respondents are also asked not to include abusive, threatening, discriminatory, defamatory, or otherwise offensive material, or personal accusations or complaints unrelated to the Advice on Puberty Suppressants. NHMRC may use screening and other administrative controls to manage exposure to such material by the public officials involved in reviewing the submissions.
How can I access the Advice on Puberty Suppressants?
The Advice on Puberty Suppressants is published on MAGICapp and the NHMRC website. MAGICapp is a guideline publishing platform that allows for ‘point of care’ use where the guidelines can be viewed on any tablet, phone or computer.
The NHMRC website will contain pdfs of the Advice on Puberty Suppressants and associated documents that can be downloaded.
Public consultation documents
- Advice on Puberty Suppressants - for public consultation
- Evidence evaluation report
- Evidence evaluation report – Supplement A
- Evidence evaluation report – Supplement B
- Research protocol
- Technical report
- Administrative report
How do I access MAGICapp?
- Visit https://www.magicapp.org/app#/guidelines
- From the guidelines list, click on Public consultation: NHMRC Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18. Note, you can use the drop-down box at the top of the screen to select National Health and Medical Research Council, or you can enter the name of the guideline in the search box.
Once you have opened the Advice on Puberty Suppressants, you will be able to view all the individual sections including the recommendation and good practice statements using the side-bar navigation tool (i.e., sections 4, 5 and 6).
A summary of the Evidence to Decision framework that was considered when developing the recommendation is available in the ‘Evidence to Decision’ tab. The full record of the GRADE Evidence to Decision framework in relation to the use of puberty suppressants in the care of trans and gender diverse young people is included in section 5.3 in the ‘Rationale’ tab following the recommendation.
- If you have any issues accessing the guidelines, please contact consultation.genderguidelines@nhmrc.gov.au
What happens after the public consultation period closes?
NHMRC will review submissions received in accordance with section 13 of the NHMRC Act. NHMRC will publish a consultation report summarising the feedback received. Any information from submissions used in the report would be anonymised. As per NHMRC requirements a public consultation report will be provided alongside the full guidelines when they are released again for public consultation.
Audiences
- Anyone from any background
Interests
- Guideline Development
Share
Share on Twitter Share on Facebook